Computational analysis of PKA-balanol interactions

Journal of Medicinal Chemistry

Volumn 44, Issue 10, 2001, Pages 1530-1539

  Wong, C F ^a,b   Hunenberger P H ^c   Akamine, P ^b,d   Narayana, N ^e   Diller, T ^b,d   McCammon, J A ^a,b,d   Taylor, S ^b,d   Xuong, N H ^d  

^a San Diego   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ETH ZURICH   (Switzerland)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BALANOL; PROTEIN KINASE INHIBITOR;

ARTICLE; BINDING AFFINITY; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ELECTRICITY; HYDROPHOBICITY; LIBRARY; MODEL; PHARMACOPHORE; PREDICTION; PROTEIN LIPID INTERACTION; RELIABILITY; STATISTICS;

AZEPINES; CATALYTIC DOMAIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DATABASES, FACTUAL; ENZYME INHIBITORS; HYDROGEN BONDING; HYDROXYBENZOIC ACIDS; LIGANDS; MODELS, MOLECULAR; POISSON DISTRIBUTION; PROTEIN BINDING;

EID: 0035837066     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm000443d     Document Type: Article

References (47)

1. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
2. Recent developments in the cell biology of basic fibroblast growth factor
3. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro
4. Increased vascularization in mice overexpressing angiopoietin-1
5. Epidermal growth factor receptor-mediated autocrine and paracrine stimulation of human transitional cell carcinoma
6. Protein kinase inhibitors: The tyrosine-specific protein kinases
7. Protein tyrosine kinase inhibitors in cancer treatment
8. Crystal structures of catalytic subunit of camp-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89-structural implications for selectivity
9. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
10. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain
11. Crystal structure of the potent natural product inhibitor balanol in complex with the catalytic subunit of cAMP-dependent protein kinase
12. Isolation of a novel tyrosine kinase inhibitor, lavendustin-a, from streptomyces-griseolavendus
13. 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase
14. A new series of Pdgf receptor tyrosine kinase inhibitors-S-substituted quinoline derivatives
15. Dianilinophthalimides-potent and selective, Atp-competitive inhibitors of the Egf-receptor protein tyrosine kinase
16. 4,5-Dianilinophthalimide - A protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity
17. 4,5-Bis(4-fluoroanilino)phthalimide - A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity
18. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class
19. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
20. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase
21. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino] and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor
22. Increasing the cellular Pkc inhibitory activity of balanol - A study of ester analogues
23. Novel Pkc inhibitory analogs of balanol with replacement of the ester functionality
24. Potent and selective Pkc inhibitory 5-membered ring analogs of balanol with replacement of the carboxamide moiety
25. Synthesis and protein kinase C inhibitory activities of balanol analogues with modification of 4-hydroxybenzamido moiety
26. Differential and selective inhibition of protein kinase A and protein kinase C in intact cells by balanol congeners
27. Inhibition of protein kinases by balanol: Specificity within the serine/threonine protein kinase subfamily
28. Free energy balance in protein folding
29. Sensitivity analysis in biomolecular simulation
30. An extended linear response method for determing free energies of hydration
31. Free energies of solvation in chloroform and water from a linear response approach
32. A new method for predicting binding affinity in computer-aided drug design
33. Binding free energy calculations for P450cam-substrate complexes
34. Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function
35. Electrostatics and diffusion of molecules in solution-simulations with the University of Houston Brownian Dynamics Program
36. Electrostatics and diffusion of molecules in solution-simulations with the University-of-Houston-Brownian Dynamics Program
37. 1001 Protein kinases redux - Towards 2000
38. Protein kinase catalytic domain sequence database: Identification of conserved features of primary structure and classification of family members
39. Determinants of ligand binding to cAMP-dependent protein kinase
40. Classical electrostatics in biology and chemistry
41. Solvation free energies estimated from macroscopic continuum theory: An accuracy assessment
42. Heteroatom effect in the Pkc inhibitory activities of perhydroazepine analogs of balanol
43. Crystal structures of the myristylated catalytic subunit of camp-dependent protein kinase reveal open and closed conformations
44. Phosphotransferase and substrate binding mechanism of the camp-dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 Angstrom structure of the complex with Mn2+ adenylyl imidodiphosphate and inhibitor peptide Pki(5-24)
45. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog